NCT06562166RecruitingPhase 2
Online Adaptive Radiotherapy for Cervical Cancer
Online Adaptive Radiotherapy (oART) in Radical Radiotherapy for Cervical Cancer - A Multi-center Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- First submitted
- 16 Aug 2024
- Start date
- Sept 2024
- Primary completion date
- Aug 2027
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT06562166
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 124
- From Sept 2024 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received radiotherapy or chemotherapy in the past
Other illness
- Have undergone radical surgery for cervical cancer
- Have a previous history of malignant tumor
- Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.
Other
- Pregnant or lactating women
Who the study is looking for
- 18-80 years old;
- Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma;
- 2018 FIGO Stage Ib3, II, IIIB and IIIC1
- Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses)
- ECOG score 0-2
- Life expectancy greater than 6 months
- Ability to remain lying down for more than 30 minutes
- Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form
- Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal
- Must complete baseline assessments and investigations required before treatment before enrolment
- be eligible for regular follow-up
Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.